drugset
drugset / Trial / NCT07032298

A Phase I Study of SSGJ-612 in Patients With Advanced Solid Tumors

NCT07032298 ↗

Phase 1 Recruiting 30 enrolled Shenyang Sunshine Pharmaceutical Co., LTD.
NaSingle-groupOpen-labelTreatment

Summary

This study is an open-label phase I study to evaluate the safety, pharmacokinetics, and antitumor activity of SSGJ-612 in patients with advanced malignant solid tumors expressing HER2.

Timeline

Start
2025-07-18
Primary completion
2026-04
Completion
2026-06

Drugs

EvaluationDrugModalityDoseRoute
Subject SSGJ-612 Unknown — Intravenous

Indications

cancer